Maintenance Imipramine Therapy for Secondary Depression in SchizophreniaA Controlled Trial
Samuel G. Siris, MD;
Paul C. Bermanzohn, MD;
Susan E. Mason, PhD;
Mitchell A. Shuwall, PhD
Arch Gen Psychiatry. 1994;51(2):109-115.
Abstract
Background
Although recent studies have documented the benefit of adjunctive antidepressant medication for the short-term treatment of certain patients with operationally defined syndromes of postpsychotic depression, the value of maintenance adjunctive antidepressant treatment in this circumstance has not been properly established.
Methods
This study examined 24 schizophrenic or Schizoaffective patients with postpsychotic depression or negative symptoms. These patients had all been benefited over the short term by the addition of adjunctive imipramine hydrochloride to their ongoing fluphenazine decanoate/benztropine mesylate regimens, and this adjunctive treatment had been successfully continued for 6 months. In a randomized double-blind protocol, treatment with adjunctive imipramine hydrochloride (mean, 233 ± 72 mg/d) was then either maintained or tapered to placebo for an ensuing 1-year trial, while treatment with fluphenazine and benztropine continued.
Results
Significantly more patients who received placebo substitution relapsed into depression (P<.001). Patients who received placebo substitution were also more likely to experience relapses into psychosis (P<.02).
Conclusions
These results support the clinical value of maintenance adjunctive imipramine therapy among initially responsive patients with postpsychotic depressions.
Author Affiliations
From the Hillside Hospital Division of the Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, Glen Oaks, NY.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial
Englisch et al.
J Psychopharmacol 2009;23:875-882.
ABSTRACT
Suicide and schizophrenia
Siris
J Psychopharmacol 2001;15:127-135.
ABSTRACT
Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents
Millan et al.
J Psychopharmacol 2000;14:114-138.
ABSTRACT
Gender Differences in Living Skills and Global Assessment of Functioning Among Outpatients with Schizophrenia
Hintikka et al.
Aust N Z J Psychiatry 1999;33:226-231.
ABSTRACT
| FULL TEXT
Antidepressant Prescribing Practices of Outpatient Psychiatrists
Olfson et al.
Arch Gen Psychiatry 1998;55:310-316.
ABSTRACT
| FULL TEXT
Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients
Hogarty et al.
Arch Gen Psychiatry 1995;52:29-41.
ABSTRACT
The Vicissitudes of Neurasthenia in Chinese Societies: Where Will It Go From the ICD-10?
Lee
Transcultural Psychiatry 1994;31:153-172.
ABSTRACT
|
